[重製版] 如何選擇EGFR突變肺癌的標靶藥物? How to Choose Targeted Therapy for EGFR-Mutated Lung Cancer?

9 次觀看·2026年2月7日

❤️Youtube Member 成為這個頻道的會員並獲得福利:
https://www.youtube.com/channel/UCBvUlnJq3TpnGtbV6fdnl2A/join
❤️Facebook 臉書粉專: https://m.facebook.com/profile.php/?id=100063644122566
❤️IG: https://instagram.com/chiaoenpeter?igshid=OGQ5ZDc2ODk2ZA==

隨著健保第三代標靶藥物的全面給付,EGFR突變肺癌的治療選擇變得更多元。這段影片將分享臨床醫師在選擇第二代與第三代標靶藥物時的考量,包括腦轉移、基因變異類型等因素,並討論第三代藥物的優勢與限制。透過這次解說,幫助病患及家屬理解選擇藥物背後的臨床邏輯,以做出更適合的治療決策。

With Taiwan’s health insurance now covering third-generation targeted therapy, treatment options for EGFR-mutated lung cancer have expanded. This video will explore the clinical considerations between second- and third-generation drugs, including factors like brain metastasis and specific gene mutations, as well as the advantages and limitations of third-generation therapies. This insight aims to help patients and families understand the clinical decision-making process behind choosing the most suitable treatment.